valsartan has been researched along with tyrosine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kitabata, H; Kuroi, A; Mochizuki, S; Muragaki, Y; Takarada, S; Tanimoto, T; Tsujioka, H; Yoshida, K | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Nako, H; Ogawa, H; Sueta, D; Tokutomi, Y; Toyama, K; Yamamoto, E | 1 |
| Wei, JR; Zhang, YL | 1 |
5 other study(ies) available for valsartan and tyrosine
| Article | Year |
|---|---|
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Topics: Acetylcholine; Amides; Animals; Antihypertensive Agents; Atherosclerosis; Biopterins; Blood Pressure; Drug Therapy, Combination; Endothelium, Vascular; Fumarates; Heart Rate; HSP90 Heat-Shock Proteins; Hyperlipidemias; Inflammation Mediators; Lipids; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rabbits; Renin; Tetrazoles; Tyrosine; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2008 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Calcium Channel Blockers; Calcium Channels; Carotid Arteries; Drug Therapy, Combination; Endothelial Cells; Hypertension; Hypoxia-Ischemia, Brain; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Tetrazoles; Tyrosine; Valine; Valsartan | 2011 |
3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model.
Topics: Animals; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Male; Myocardium; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Tetrazoles; Tyrosine; Valine; Valsartan | 2013 |